Tau‐targeting therapies, including active vaccines (AADvac1), antibodies (Bepranemab), and Rho‐associated protein kinase inhibitor (Fasudil), which acts through enhancing tau autophagy and reducing tau mRNA, as well as an intrathecal antisense oligonucleotide (NIO752) that acts by interfering with the translation of tau mRNA, are being evaluated in clinical trials for their efficacy and safety in PSP, CBD, and other tauopathies, including AD. The gene discussed is MAPT; the disease is Alzheimer disease.